Metastatic breast cancer: symptoms and diagnosis
The symptoms of metastatic cancer depend on the location of the new tumor. For example, a tumor in the brain may cause headaches or seizures. Or a tumor in the liver may cause jaundice (yellowing of the skin) or abdominal swelling.
In some cases, the metastatic breast cancer tumor does not cause symptoms. It is discovered during other medical exams or tests. It is also possible (but not common) for the primary tumor to be discovered after the metastatic tumor is found.21
A pathologist will examine samples of the tumor under a microscope to determine whether it is primary or metastatic. If it is primary, the cells will look like abnormal versions of the cells in the area from which the sample was taken. If the tumor cells do not resemble those in the area from which they are taken, it is metastatic. The primary site can be determined by looking for specific markers or antigens on the cancer cells.21
Additional tests, such as CT scans, x-rays, and blood work, will be performed to determine the extent and severity of the cancer.26
Currently, there are several treatment options available for metastatic (or advanced) breast cancer: hormonal therapy and chemotherapy, including targeted therapy.22
Check out GlaxoSmithKline's Tykerb® CARES support program to help patients and the healthcare providers who treat them.
Questions about treatment with TYKERB?
Ask the Experts
Get the latest information
from www.TYKERB.com
Indication
TYKERB is indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin® (trastuzumab).
Important Safety Information
Some women may develop liver damage while taking TYKERB. The cause of this damage is not known. In some cases, liver damage may be severe and may cause death. Your doctor should test your liver before and during treatment with TYKERB to check for signs of liver damage. You should contact your doctor if you have itching, yellow eyes or skin, dark urine, pain in your right upper side of your belly or feel very tired. If you develop liver damage during your treatment, your doctor may tell you to stop taking TYKERB. Before taking TYKERB, tell your doctor if you have liver problems. You may need a lower dose of TYKERB.
Before taking TYKERB, tell your doctor if you have heart problems. As with other treatments for HER2-positive advanced or metastatic breast cancer, there have been reports of changes in how the heart pumps blood through the body and how the heart beats. Call your doctor right away if you are short of breath, have rapid heartbeats (palpitations), or feel very tired.
Some people taking TYKERB have reported diarrhea. In some cases, diarrhea can be severe. Call your doctor right away if you have diarrhea. It is important to manage diarrhea with medicine as soon as it begins. Severe diarrhea may need to be treated with electrolytes and fluids given by mouth or by vein. Treatment with TYKERB may have to be delayed for a while or stopped completely.
If you have a dry cough or have shortness of breath, talk with your doctor. These may be signs of inflammation in the lungs.
Women should not become pregnant when taking TYKERB because the unborn baby may be harmed.
The most common side effects reported by patients taking TYKERB and Xeloda were diarrhea; vomiting; feeling sick to your stomach (nausea); feeling tired; red, painful hands and feet; and rash.
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines and herbal and dietary supplements.
Because TYKERB is currently indicated to be taken with another medicine called Xeloda, be sure to talk with your doctor about any medicines and supplements that should be avoided when taking Xeloda.
Please see complete US Prescribing Information for TYKERB.
Herceptin is a registered trademark of Genentech, Inc.
Xeloda is a registered trademark of Roche Laboratories Inc.
Photos are for illustrative purposes only.